<DOC>
	<DOCNO>NCT02813460</DOCNO>
	<brief_summary>The purpose study evaluate double-blinded fashion taste overall acceptability profile different ALS-008176 oral liquid formulation compare reference formulation ( ALS-008176 : 60 milligram per milliliter ( mg/mL ) oral suspension without sweetener/flavor ) pediatric clinical development commercialization .</brief_summary>
	<brief_title>Study Assess Taste Profile Different ALS-008176 Oral Liquid Formulations Healthy Adult Participants</brief_title>
	<detailed_description />
	<criteria>Participant must man woman 18 65 year age , inclusive , Screening Participant must sign informed consent form ( ICF ) indicate understands purpose , procedure require , study willing participate study Participant must willing able adhere prohibition restriction specify protocol A female participant must nonchildbearing potential , define either : 1 ) Postmenopausal ; 2 ) A postmenopausal state define menses least 12 month without alternative medical cause serum follicle stimulate hormone ( FSH ) level postmenopausal range ( [ &gt; ] 40 international unit per liter [ IU/L ] milli international unit per milliliter [ mIU/mL ] ) , 3 ) Permanently sterile ; 4 ) Permanent sterilization method include hysterectomy , bilateral salpingectomy , bilateral tubal occlusion/ligation procedure ( without reversal operation ) , bilateral oophorectomy During study minimum one spermatogenesis cycle ( define approximately 90 day ) receiving ( last dose ) study drug , male participant 1 ) sexually active woman childbearing potential must agree use barrier method contraception ( example , condom spermicidal foam/gel/film/cream/suppository ) ; 2 ) sexually active pregnant woman must use condom ; 3 ) must agree donate sperm Female partner male participant must either surgically sterilize , postmenopausal , childbearing potential , must agree use least one follow contraceptive method 90 day follow final dose study drug : nonhormonal intrauterine device spermicide ; contraceptive sponge spermicide , diaphragm spermicide , cervical cap spermicide , oral , implantable , transdermal , injectablehormonal contraceptive A female participant must negative serum beta human chorionic gonadotropin ( beta hCG ) pregnancy test Screening negative urine pregnancy test Day 1 predose A female participant must agree donate egg study least 90 day receive ( last dose ) study drug Participant must body mass index ; weight ( kilogram per height square [ kg/height^2 [ m^2 ] ) 18.0 30.0 kilogram per meter square ( kg/m^2 ) ( inclusive ) Screening Participant must nonsmoker and/or use chew tobacco least 3 month prior Screening Participant must able taste smell normally , opinion , time throughout study duration . Participants impaired sense taste and/or smell due condition allergic rhinitis , common cold sinusitis eligible take part continue study Participant must able read write Participant mouth pathology include , limited , pain , ulcer , edema , mucosal erosion , gingivitis and/or ( dental ) abscess , receive treatment oral pathology oral treatment disease Participant history current clinically significant medical illness include Sjogren 's syndrome , cardiac arrhythmia cardiac disease , pernicious anemia , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Participant history clinically significant drug allergy , limited , sulfonamides penicillin , drug allergy diagnose previous study experimental drug Participant presence febrile illness symptom upper low respiratory tract infection 14 day ( first ) dose study drug Participant history drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 5th edition ) ( DSMV ) criterion within 5 year screen positive test result ( ) alcohol and/or drug abuse ( include barbiturate , opiate , cocaine , amphetamine , methadone , benzodiazepine , methamphetamine , tetrahydrocannabinol , phencyclidine , tricyclic antidepressant ) Screening Participant known allergy , hypersensitivity , intolerance ALS008176 excipients Participant receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 90 day plan first dose study drug Participant man plan father child enrol study within 90 day last dose study drug , unwilling use acceptable method contraception Vulnerable participant ( example , incarcerated individual ) Participant employee Investigator study site , direct involvement propose study study direction Investigator study site , well family member employee Investigator participant employee Johnson &amp; Johnson Participant condition , opinion Investigator , participation would best interest participant ( example , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>